RBC Capital analyst Luca Issi lowered the firm’s price target on Intellia Therapeutics (NTLA) to $37 from $47 and keeps an Outperform rating on the shares after its Q4 results. The company’s clinical execution remains on track though the management has sharpened its focus on cost containment, the analyst tells investors in a research note. The firm adds that Intellia focusing on the late-stage pipeline is the right pragmatic decision, and RBC remains a buyer on the stock that is “best positioned for in vivo gene editing” and given its “three highly de-risked assets”.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating
- Goldman downgrades Intellia to Sell on challenging commercial outlook
- Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
- Intellia Therapeutics: Strong Cash Position and Strategic Cost Reductions Drive Buy Rating and Increased Price Target
- Intellia Therapeutics price target raised to $14 from $12 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue